OncoSec Medical Incの発行済株式数
OncoSec Medical Incの発行済株式数は何ですか。
OncoSec Medical Incの発行済株式数は5.963Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
NASDAQのセクタHealth Careにおける発行済株式数の企業と比べるOncoSec Medical Inc
OncoSec Medical Incは何をしますか。
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Incと類似の発行済株式数
- The Indian Card Clothingの発行済株式数は5.941Mです。
- Sharda Motor Industriesの発行済株式数は5.946Mです。
- United (Martins Ferry, OH)の発行済株式数は5.951Mです。
- RENN Fundの発行済株式数は5.952Mです。
- VelocityShares 3x Long Silver ETNの発行済株式数は5.953Mです。
- Pyrolyx AGの発行済株式数は5.961Mです。
- OncoSec Medical Incの発行済株式数は5.963Mです。
- GKWの発行済株式数は5.967Mです。
- Harvest Capital Credit Corpの発行済株式数は5.968Mです。
- Gabelli Global Utility & Income Trustの発行済株式数は5.969Mです。
- Aytu BioPharma Incの発行済株式数は5.972Mです。
- Rasandik Engineering Industries Indiaの発行済株式数は5.975Mです。
- Flaherty & Crumrine Investment Grade Preferred Income Fundの発行済株式数は5.975Mです。